Theodore Karrison to Humans
This is a "connection" page, showing publications Theodore Karrison has written about Humans.
Connection Strength
1.089
-
Nonparametric inference in the accelerated failure time model using restricted means. Lifetime Data Anal. 2022 01; 28(1):23-39.
Score: 0.028
-
Effects of driving distance and transport time on mortality among Level I and II traumas occurring in a metropolitan area. J Trauma Acute Care Surg. 2018 Oct; 85(4):756-765.
Score: 0.022
-
Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials. 2018 04; 15(2):178-188.
Score: 0.021
-
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.
Score: 0.020
-
Building firm foundations for therapy development. J Natl Cancer Inst. 2015 Mar; 107(3).
Score: 0.017
-
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. J Clin Oncol. 2015 Jan 01; 33(1):36-41.
Score: 0.017
-
Estimation of progression-free survival in the randomized discontinuation trial design. J Clin Oncol. 2013 Feb 20; 31(6):814.
Score: 0.015
-
Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9.
Score: 0.015
-
Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents. J Biopharm Stat. 2009; 19(3):524-9.
Score: 0.011
-
Modeling major lung resection outcomes using classification trees and multiple imputation techniques. Eur J Cardiothorac Surg. 2008 Nov; 34(5):1085-9.
Score: 0.011
-
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61.
Score: 0.010
-
Continuous Bayesian adaptive randomization based on event times with covariates by Cheung et al., Statistics in Medicine 2006; 25:55-70. Stat Med. 2007 Jul 10; 26(15):3050-2; author reply 3052-4.
Score: 0.010
-
Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res. 2007 Feb 01; 13(3):781-2.
Score: 0.010
-
A group sequential, response-adaptive design for randomized clinical trials. Control Clin Trials. 2003 Oct; 24(5):506-22.
Score: 0.008
-
Factors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003 Oct; 99(4):644-52.
Score: 0.008
-
The aspect ratio (dome/neck) of ruptured and unruptured aneurysms. J Neurosurg. 2003 Sep; 99(3):447-51.
Score: 0.008
-
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538.
Score: 0.008
-
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation. Eur Urol Oncol. 2024 Feb; 7(1):83-90.
Score: 0.008
-
Underlying intracranial atherosclerotic disease is associated with worse outcomes in acute large vessel occlusion undergoing endovascular thrombectomy. J Stroke Cerebrovasc Dis. 2023 Aug; 32(8):107227.
Score: 0.008
-
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 05 15; 133(10).
Score: 0.008
-
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.
Score: 0.008
-
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial. Eur Urol. 2023 08; 84(2):156-163.
Score: 0.008
-
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2023 10 01; 117(2):370-377.
Score: 0.008
-
Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial. J Clin Oncol. 2023 06 10; 41(17):3217-3224.
Score: 0.008
-
Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial. J Clin Oncol. 2023 06 10; 41(17):3203-3216.
Score: 0.008
-
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2023 03 28; 7(6):963-970.
Score: 0.008
-
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Eur J Haematol. 2023 May; 110(5):564-570.
Score: 0.007
-
Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clin Lung Cancer. 2023 05; 24(3):e117-e121.
Score: 0.007
-
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res. 2022 12 01; 28(23):5040-5048.
Score: 0.007
-
The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy - Authors' reply. Lancet. 2022 09 17; 400(10356):885-886.
Score: 0.007
-
D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia. Blood Adv. 2022 09 13; 6(17):5146-5151.
Score: 0.007
-
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
Score: 0.007
-
Troxacitabine in patients with refractory leukemia. J Clin Oncol. 2002 Aug 01; 20(15):3356; author reply 3356-7.
Score: 0.007
-
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 07 01; 107(7):1608-1618.
Score: 0.007
-
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2022 Dec; 20(6):510-514.
Score: 0.007
-
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
Score: 0.007
-
The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. Int J Radiat Oncol Biol Phys. 2022 10 01; 114(2):266-274.
Score: 0.007
-
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022 05 14; 399(10338):1886-1901.
Score: 0.007
-
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.
Score: 0.007
-
Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care. Pharmacogenet Genomics. 2022 04 01; 32(3):79-86.
Score: 0.007
-
Data management and statistical methods used in the analysis of balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and therapy-related acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002 Apr; 33(4):346-61.
Score: 0.007
-
Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial. Anesth Analg. 2022 11 01; 135(5):929-940.
Score: 0.007
-
Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer. 2022 Apr 15; 128(8):1649-1657.
Score: 0.007
-
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
Score: 0.007
-
Sizes of ruptured and unruptured aneurysms in relation to their sites and the ages of patients. J Neurosurg. 2002 Jan; 96(1):64-70.
Score: 0.007
-
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
Score: 0.007
-
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
Score: 0.007
-
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 08 20; 39(24):2647-2655.
Score: 0.007
-
A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer. 2021 08 01; 127(15):2631-2640.
Score: 0.007
-
Coagulopathy as a Surrogate of Severity of Injury in Penetrating Brain Injury. J Neurotrauma. 2021 Jun 01; 38(13):1821-1826.
Score: 0.006
-
The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people. J Gerontol A Biol Sci Med Sci. 2001 Jan; 56(1):M36-41.
Score: 0.006
-
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
Score: 0.006
-
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
Score: 0.006
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
Score: 0.006
-
ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol. JCO Glob Oncol. 2020 07; 6:983-990.
Score: 0.006
-
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243.
Score: 0.006
-
Does pneumonectomy for lung cancer adversely influence long-term survival? J Thorac Cardiovasc Surg. 2000 Mar; 119(3):440-8.
Score: 0.006
-
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606.
Score: 0.006
-
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152.
Score: 0.006
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.006
-
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24.
Score: 0.006
-
The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther. 2019 12; 106(6):1179-1183.
Score: 0.006
-
Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer. 1999 Aug 01; 86(3):546-7.
Score: 0.006
-
Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. J Clin Pharmacol. 2019 12; 59(12):1632-1640.
Score: 0.006
-
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 08; 186(4):549-560.
Score: 0.006
-
Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
Score: 0.006
-
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
Score: 0.006
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
Score: 0.006
-
Analytical Differences in Intraoperative Parathyroid Hormone Assays. J Appl Lab Med. 2019 03; 3(5):788-798.
Score: 0.006
-
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636.
Score: 0.006
-
Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999 Jan 06; 91(1):80-5.
Score: 0.006
-
Major Adverse Cardiac Events and Mortality Associated with Electroconvulsive Therapy: A Systematic Review and Meta-analysis. Anesthesiology. 2019 01; 130(1):83-91.
Score: 0.006
-
Recurrent miscarriage (REMIS) study: how should data from women who do not become pregnant be handled? Control Clin Trials. 1998 Oct; 19(5):430-9.
Score: 0.006
-
Low-Dose Abiraterone With Food: Rebutting an Editorial. J Clin Oncol. 2018 10 20; 36(30):3060-3061.
Score: 0.005
-
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
Score: 0.005
-
Season of birth and cockroach allergen sensitization in children with asthma. J Allergy Clin Immunol. 1998 Apr; 101(4 Pt 1):566-8.
Score: 0.005
-
Skin test reactivity to indoor allergens as a marker of asthma severity in children with asthma. Ann Allergy Asthma Immunol. 1998 Apr; 80(4):303-8.
Score: 0.005
-
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395.
Score: 0.005
-
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
Score: 0.005
-
Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol. 2018 04; 31(4):598-606.
Score: 0.005
-
Pregnancy outcomes and ethanol cook stove intervention: A randomized-controlled trial in Ibadan, Nigeria. Environ Int. 2018 02; 111:152-163.
Score: 0.005
-
Sensitization to indoor allergens and the risk for asthma hospitalization in children. Ann Allergy Asthma Immunol. 1997 Nov; 79(5):455-9.
Score: 0.005
-
The PATHWAYS church-based weight loss program for urban African-American women at risk for diabetes. Diabetes Care. 1997 Oct; 20(10):1518-23.
Score: 0.005
-
Randomized Controlled Ethanol Cookstove Intervention and Blood Pressure in Pregnant Nigerian Women. Am J Respir Crit Care Med. 2017 06 15; 195(12):1629-1639.
Score: 0.005
-
Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations. Control Clin Trials. 1997 Apr; 18(2):151-67.
Score: 0.005
-
Effect of a clean stove intervention on inflammatory biomarkers in pregnant women in Ibadan, Nigeria: A randomized controlled study. Environ Int. 2017 Jan; 98:181-190.
Score: 0.005
-
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
Score: 0.005
-
WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck. Oncotarget. 2016 Jul 05; 7(27):42527-42538.
Score: 0.005
-
Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task. Bone Marrow Transplant. 2016 Oct; 51(10):1342-1349.
Score: 0.005
-
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol. 2016 06 20; 34(18):2165-71.
Score: 0.005
-
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
Score: 0.005
-
Comparison of Perioperative and Early Oncologic Outcomes between Open and Robotic Assisted Laparoscopic Prostatectomy in a Contemporary Population Based Cohort. J Urol. 2016 07; 196(1):76-81.
Score: 0.005
-
Confidence intervals for median survival times under a piecewise exponential model with proportional hazards covariate effects. Stat Med. 1996 Jan 30; 15(2):171-82.
Score: 0.005
-
Comparison of median survival times with adjustment for covariates. Stat Med. 1995 Dec 15; 14(23):2537-53.
Score: 0.005
-
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.
Score: 0.005
-
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
Score: 0.005
-
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93.
Score: 0.005
-
Increased utilization of postmastectomy radiotherapy in the United States from 2003 to 2011 in patients with one to three tumor positive nodes. J Surg Oncol. 2015 Dec; 112(8):809-14.
Score: 0.005
-
Patterns of Hydrocephalus Caused by Congenital Toxoplasma gondii Infection Associate With Parasite Genetics. Clin Infect Dis. 2015 Dec 15; 61(12):1831-4.
Score: 0.004
-
Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants. Clin Infect Dis. 2015 Dec 15; 61(12):1815-24.
Score: 0.004
-
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
Score: 0.004
-
Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968.
Score: 0.004
-
The treatment of rheumatic carditis: a review and meta-analysis. Medicine (Baltimore). 1995 Jan; 74(1):1-12.
Score: 0.004
-
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
Score: 0.004
-
Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clin Cancer Res. 2015 Jan 15; 21(2):365-72.
Score: 0.004
-
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.
Score: 0.004
-
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
Score: 0.004
-
Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One. 2014; 9(7):e100586.
Score: 0.004
-
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
Score: 0.004
-
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
Score: 0.004
-
Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors. J Clin Pharmacol. 2014 Jun; 54(6):682-7.
Score: 0.004
-
Early removal of urethral catheter with suprapubic tube drainage versus urethral catheter drainage alone after robot-assisted laparoscopic radical prostatectomy. J Urol. 2014 Jul; 192(1):89-95.
Score: 0.004
-
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
Score: 0.004
-
Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood. 2014 Feb 13; 123(7):1069-78.
Score: 0.004
-
Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc. Blood. 2014 Jan 09; 123(2):228-38.
Score: 0.004
-
Quantitative allelic test--a fast test for very large association studies. Genet Epidemiol. 2013 Dec; 37(8):831-9.
Score: 0.004
-
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
Score: 0.004
-
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
Score: 0.004
-
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668.
Score: 0.004
-
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
Score: 0.004
-
Public attitudes about the use of chronological age as a criterion for allocating health care resources. Gerontologist. 1993 Feb; 33(1):74-80.
Score: 0.004
-
A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. Cancer. 2013 May 01; 119(9):1683-9.
Score: 0.004
-
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.
Score: 0.004
-
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15.
Score: 0.004
-
Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009). Clin Infect Dis. 2012 Jun; 54(11):1595-605.
Score: 0.004
-
Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res. 2012 May 01; 18(9):2526-33.
Score: 0.004
-
Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.
Score: 0.003
-
Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7.
Score: 0.003
-
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
Score: 0.003
-
Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis. 2011 Dec; 53(11):1081-9.
Score: 0.003
-
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.
Score: 0.003
-
Increased all-cause and cardiac morbidity and mortality associated with the diagonal earlobe crease: a prospective cohort study. Am J Med. 1991 Sep; 91(3):247-54.
Score: 0.003
-
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1629-32.
Score: 0.003
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.003
-
Efficacy of daily routine chest radiographs in intubated, mechanically ventilated patients. Crit Care Med. 1991 May; 19(5):689-93.
Score: 0.003
-
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol. 2011 Apr; 34(2):150-4.
Score: 0.003
-
Generation of comprehensive thoracic oncology database--tool for translational research. J Vis Exp. 2011 Jan 22; (47).
Score: 0.003
-
MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54.
Score: 0.003
-
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6.
Score: 0.003
-
Outcomes in black patients with early breast cancer treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):392-9.
Score: 0.003
-
Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010 Jun 01; 28(16):2653-9.
Score: 0.003
-
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 2010 Jan 29; 5(1):e8972.
Score: 0.003
-
Neoplasms with schwannian differentiation express transcription factors known to regulate normal schwann cell development. Int J Surg Pathol. 2010 Dec; 18(6):449-57.
Score: 0.003
-
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7.
Score: 0.003
-
Common fragile sites are characterized by histone hypoacetylation. Hum Mol Genet. 2009 Dec 01; 18(23):4501-12.
Score: 0.003
-
Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83.
Score: 0.003
-
Frequency of failure to inform patients of clinically significant outpatient test results. Arch Intern Med. 2009 Jun 22; 169(12):1123-9.
Score: 0.003
-
What does it cost physician practices to interact with health insurance plans? Health Aff (Millwood). 2009 Jul-Aug; 28(4):w533-43.
Score: 0.003
-
A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009 Jul; 56(1):97-103.
Score: 0.003
-
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34.
Score: 0.003
-
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
Score: 0.003
-
A controlled trial of extended radical versus radical mastectomy. Ten-year results. Cancer. 1989 Jan 01; 63(1):188-95.
Score: 0.003
-
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
Score: 0.003
-
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug; 44(12):1684-92.
Score: 0.003
-
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.
Score: 0.003
-
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
Score: 0.003
-
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
Score: 0.003
-
Reproducibility and sources of variability in radiographic texture analysis of densitometric calcaneal images. J Clin Densitom. 2008 Apr-Jun; 11(2):211-20.
Score: 0.003
-
Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 2008 Jan; 44(1):10-22.
Score: 0.003
-
Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus. Arthritis Rheum. 2007 Jun 15; 57(5):845-50.
Score: 0.003
-
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther. 2007 Apr; 6(4):490-3.
Score: 0.002
-
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007 Feb; 127(2):197-205.
Score: 0.002
-
Safety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial. Am J Chin Med. 2007; 35(3):407-14.
Score: 0.002
-
Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics. 2006 Aug; 118(2):e379-90.
Score: 0.002
-
Radiographic texture analysis of densitometer-generated calcaneus images differentiates postmenopausal women with and without fractures. Osteoporos Int. 2006 Oct; 17(10):1472-82.
Score: 0.002
-
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006 Jul; 5(7):766-70.
Score: 0.002
-
Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis. 2006 May 15; 42(10):1383-94.
Score: 0.002
-
Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels. Circulation. 1986 Apr; 73(4):740-8.
Score: 0.002
-
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9.
Score: 0.002
-
Functional equality of coordinating centers in a multicenter clinical trial. Experience of the International Mexiletine and Placebo Antiarrhythmic Coronary Trial (IMPACT). Control Clin Trials. 1986 Mar; 7(1):38-52.
Score: 0.002
-
Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proc Natl Acad Sci U S A. 2006 Jan 24; 103(4):1030-5.
Score: 0.002
-
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
Score: 0.002
-
Studies in hemolysis in glucose-6-phosphate dehydrogenase-deficient African American neonates. Clin Chim Acta. 2006 Mar; 365(1-2):177-82.
Score: 0.002
-
Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005 May; 45(5):538-46.
Score: 0.002
-
Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 2005 Apr 15; 65(8):3146-54.
Score: 0.002
-
A controlled trial of extended radical mastectomy. Cancer. 1985 Feb 15; 55(4):880-91.
Score: 0.002
-
Folate binding protein and the estrogen receptor in breast cancer. Cancer Detect Prev. 1985; 8(1-2):71-5.
Score: 0.002
-
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
Score: 0.002
-
Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. Cancer Chemother Pharmacol. 2005 Apr; 55(4):333-342.
Score: 0.002
-
The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14198-203.
Score: 0.002
-
Fetal loss associated with excess thyroid hormone exposure. JAMA. 2004 Aug 11; 292(6):691-5.
Score: 0.002
-
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Invest New Drugs. 2004 Aug; 22(3):323-7.
Score: 0.002
-
Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial. Ann Intern Med. 2004 Jul 06; 141(1):23-7.
Score: 0.002
-
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70.
Score: 0.002
-
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15; 22(8):1382-8.
Score: 0.002
-
Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res. 2004 Mar 01; 64(5):1757-64.
Score: 0.002
-
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
Score: 0.002
-
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003 Oct; 170(4 Pt 1):1141-5.
Score: 0.002
-
Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg. 2003 Sep; 238(3):433-41; discussion 442-5.
Score: 0.002
-
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.
Score: 0.002
-
Predictors of emergency medical services utilization by elders. Acad Emerg Med. 2003 Jan; 10(1):52-8.
Score: 0.002
-
The pathological findings of breast cancer in patients surviving 25 years after radical mastectomy. Cancer. 1982 Nov 15; 50(10):2131-8.
Score: 0.002
-
Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 2002 Nov 15; 62(22):6717-23.
Score: 0.002
-
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
Score: 0.002
-
Evaluation of the direct antiglobulin (Coombs') test for identifying newborns at risk for hemolysis as determined by end-tidal carbon monoxide concentration (ETCOc); and comparison of the Coombs' test with ETCOc for detecting significant jaundice. J Perinatol. 2002 Jul-Aug; 22(5):341-7.
Score: 0.002
-
Isoimmunization is unlikely to be the cause of hemolysis in ABO-incompatible but direct antiglobulin test-negative neonates. Pediatrics. 2002 Jul; 110(1 Pt 1):127-30.
Score: 0.002
-
Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther. 2002 Jan; 300(1):118-23.
Score: 0.002
-
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2(1):43-7.
Score: 0.002
-
HLA-G genotypes and pregnancy outcome in couples with unexplained recurrent miscarriage. Mol Hum Reprod. 2001 Dec; 7(12):1167-72.
Score: 0.002
-
Factors associated with older patients' satisfaction with care in an inner-city emergency department. Ann Emerg Med. 2001 Aug; 38(2):140-5.
Score: 0.002
-
Failed vaginal birth after a cesarean section: how risky is it? I. Maternal morbidity. Am J Obstet Gynecol. 2001 Jun; 184(7):1365-71; discussion 1371-3.
Score: 0.002
-
Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 2001 Apr 01; 61(7):2833-7.
Score: 0.002
-
Early revisit, hospitalization, or death among older persons discharged from the ED. Am J Emerg Med. 2001 Mar; 19(2):125-9.
Score: 0.002
-
A benzodiazepine hypnotic facilitates adaptation of circadian rhythms and sleep-wake homeostasis to an eight hour delay shift simulating westward jet lag. Sleep. 2000 Nov 01; 23(7):915-27.
Score: 0.002
-
Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8.
Score: 0.002
-
Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 2000 Apr; 67(4):398-404.
Score: 0.002
-
Quality of diabetes care in community health centers. Am J Public Health. 2000 Mar; 90(3):431-4.
Score: 0.002
-
Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 2000 Jan 19; 283(3):367-72.
Score: 0.002
-
The child with congenital toxoplasmosis. Curr Clin Top Infect Dis. 2000; 20:189-208.
Score: 0.002
-
Peripartum hysterectomy. J Perinat Med. 2000; 28(6):472-81.
Score: 0.002
-
Appropriateness of medication selection for older persons in an urban academic emergency department. Acad Emerg Med. 1999 Dec; 6(12):1232-42.
Score: 0.001
-
Older patients' health-related quality of life around an episode of emergency illness. Ann Emerg Med. 1999 Nov; 34(5):595-603.
Score: 0.001
-
Safety of peripheral intravenous catheters in children. Infect Control Hosp Epidemiol. 1999 Nov; 20(11):736-40.
Score: 0.001
-
Treatment of ductal carcinoma in situ. N Engl J Med. 1999 Sep 23; 341(13):999-1000.
Score: 0.001
-
The effect of alcohol abuse on the health status of older adults seen in the emergency department. Am J Drug Alcohol Abuse. 1999 Aug; 25(3):529-42.
Score: 0.001
-
Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial. Lancet. 1999 Jul 31; 354(9176):365-9.
Score: 0.001
-
The CD34+ cell concentration in peripheral blood predicts CD34+ cell yield in the leukapheresis product. Cytotherapy. 1999; 1(2):141-6.
Score: 0.001
-
Transmission disequilibrium of maternally-inherited CTLA-4 microsatellite alleles in idiopathic recurrent miscarriage. J Reprod Immunol. 1998 Nov; 40(2):147-57.
Score: 0.001
-
Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology. 1998 May; 114(5):902-11.
Score: 0.001
-
Dose-related effects of oral acetaminophen on cold-induced pain: a double-blind, randomized, placebo-controlled trial. Clin Pharmacol Ther. 1998 Mar; 63(3):379-83.
Score: 0.001
-
Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997 Nov; 30(5):621-31.
Score: 0.001
-
Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 1997 May; 49(5):697-702.
Score: 0.001
-
Randomized, prospective, double-blind study of the effects on pain perception of lidocaine jelly versus plain lubricant during outpatient rigid cystoscopy. J Urol. 1997 Jan; 157(1):90-4.
Score: 0.001
-
Hospital utilization patterns and costs for adult sickle cell patients in Illinois. Public Health Rep. 1997 Jan-Feb; 112(1):44-51.
Score: 0.001
-
Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995 Jul; 96(1):520-7.
Score: 0.001
-
Mode of delivery and perinatal results in breech presentation. Am J Obstet Gynecol. 1994 Jul; 171(1):28-34.
Score: 0.001
-
Factors influencing neonatal outcomes in the very-low-birth-weight fetus (< 1500 grams) with a breech presentation. Am J Obstet Gynecol. 1994 Jul; 171(1):35-42.
Score: 0.001
-
The correlation between donor characteristics and the success of human islet isolation. Transplantation. 1994 Mar 27; 57(6):954-8.
Score: 0.001
-
Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population. Pediatrics. 1994 Jan; 93(1):114-8.
Score: 0.001
-
Autoantibodies and pregnancy history in a healthy population. Am J Obstet Gynecol. 1993 Jul; 169(1):143-7.
Score: 0.001
-
Acute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques. Int J Radiat Oncol Biol Phys. 1993 Jan 15; 25(2):359-71.
Score: 0.001
-
Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec; 1(7):541-5.
Score: 0.001
-
Localized prostate cancer: use of serial prostate-specific antigen measurements during radiation therapy. Radiology. 1992 Jul; 184(1):271-4.
Score: 0.001
-
Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology. 1992 Jun; 102(6):1957-61.
Score: 0.001
-
The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology. 1992; 49(6):454-60.
Score: 0.001
-
Health status of Air Force veterans occupationally exposed to herbicides in Vietnam. I. Physical health. JAMA. 1990 Oct 10; 264(14):1824-31.
Score: 0.001
-
Methyl transferase activity in secondary leukemia. Basic Life Sci. 1990; 53:277-89.
Score: 0.001
-
Heterogeneity of O6-alkylguanine-DNA alkyltransferase activity in peripheral blood lymphocytes: relationship between this activity in lymphocytes and in lymphoblastoid lines from normal controls and from patients with Hodgkin's disease or non-Hodgkin's lymphoma. Cancer Res. 1989 Oct 01; 49(19):5339-44.
Score: 0.001
-
Chromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemia. Mutat Res. 1989 Apr; 216(2):119-26.
Score: 0.001
-
Low O6-alkylguanine DNA alkyltransferase activity in the peripheral blood lymphocytes of patients with therapy-related acute nonlymphocytic leukemia. Cancer Res. 1988 Jun 01; 48(11):3084-9.
Score: 0.001
-
Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol. 1988 Mar; 254(3 Pt 1):E349-57.
Score: 0.001
-
Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest. 1988 Feb; 81(2):435-41.
Score: 0.001
-
Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer. 1987 May 15; 59(10):1744-50.
Score: 0.001
-
Histologic features associated with long-term survival in breast cancer. Hum Pathol. 1986 Oct; 17(10):1015-21.
Score: 0.001
-
Calculation of the systemic delivery rate of insulin in normal man. J Clin Endocrinol Metab. 1986 Jul; 63(1):113-8.
Score: 0.001
-
Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc Natl Acad Sci U S A. 1986 Apr; 83(8):2684-8.
Score: 0.001
-
The limitations to and valid use of C-peptide as a marker of the secretion of insulin. Diabetes. 1986 Apr; 35(4):379-86.
Score: 0.001
-
Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest. 1986 Jan; 77(1):98-105.
Score: 0.001
-
Fast walking velocity in health and Duchenne muscular dystrophy: a statistical analysis. Arch Phys Med Rehabil. 1984 Oct; 65(10):573-8.
Score: 0.001
-
Staging of breast cancer and survival rates. An assessment based on 50 years of experience with radical mastectomy. JAMA. 1982 Sep 17; 248(11):1337-41.
Score: 0.000
-
A statistical analysis of the loss of muscle strength in Duchenne's muscular dystrophy. Res Commun Chem Pathol Pharmacol. 1982 Jul; 37(1):123-38.
Score: 0.000
-
Prognostic significance of immunological tests in lung cancer. Clin Exp Immunol. 1981 Feb; 43(2):362-9.
Score: 0.000